| scholarly article | Q13442814 |
| P50 | author | Richard Hill | Q39965266 |
| Paul Cox | Q56896640 | ||
| Giannis Sokratous | Q87715426 | ||
| Simon Cragg | Q21389698 | ||
| P2093 | author name string | Keyoumars Ashkan | |
| Alison Howarth | |||
| Sang Y Lee | |||
| Geoffrey J Pilkington | |||
| Patricia A Madureira | |||
| Claire Simms | |||
| Olivia Allen | |||
| Andy D Morley | |||
| Karina Mihajluk | |||
| Nitesh Kerai | |||
| P2860 | cites work | Brain tumor cell line authentication, an efficient alternative to capillary electrophoresis by using a microfluidics-based system | Q37492170 |
| Current and investigational drug strategies for glioblastoma | Q38207317 | ||
| Glioblastoma multiforme: State of the art and future therapeutics | Q38225874 | ||
| Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. | Q38459342 | ||
| Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies | Q38525123 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis | Q38919625 | ||
| Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling | Q39145672 | ||
| European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. | Q39359091 | ||
| DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. | Q39424192 | ||
| Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells | Q40151256 | ||
| Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism | Q40476934 | ||
| Resveratrol induces DNA damage in colon cancer cells by poisoning topoisomerase II and activates the ATM kinase to trigger p53-dependent apoptosis | Q40963962 | ||
| Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1. | Q41636714 | ||
| Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma | Q42375231 | ||
| Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. | Q45933704 | ||
| Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children | Q46732236 | ||
| Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme | Q48181079 | ||
| Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study | Q48285313 | ||
| Venerable brain-cancer cell line faces identity crisis | Q48524968 | ||
| Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. | Q48675680 | ||
| Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer. | Q52423960 | ||
| Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. | Q55463299 | ||
| Expression of p53 and prognosis in children with malignant gliomas. | Q55473725 | ||
| Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. | Q55512580 | ||
| Cell-cycle arrest versus cell death in cancer therapy | Q73677622 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Characterization of a novel anti-cancer compound for astrocytomas | Q28543237 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. | Q30373363 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
| Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. | Q33198814 | ||
| Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy | Q33767861 | ||
| Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma | Q34062017 | ||
| Influence of topoisomerase II inhibitors and ionizing radiation on growth arrest and cell death pathways in the breast tumor cell | Q34231690 | ||
| Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. | Q34446549 | ||
| IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group | Q34458930 | ||
| NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells | Q34459467 | ||
| EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors | Q34460151 | ||
| Origin of the U87MG glioma cell line: Good news and bad news | Q34539119 | ||
| Current and future developments in the use of temozolomide for the treatment of brain tumours | Q34571908 | ||
| Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group | Q34722440 | ||
| Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group | Q34722864 | ||
| Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist | Q35718965 | ||
| Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition | Q35740037 | ||
| High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures | Q35759165 | ||
| BET inhibition as a new strategy for the treatment of gastric cancer | Q36040347 | ||
| A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | Q36621800 | ||
| Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. | Q37065952 | ||
| Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. | Q37084096 | ||
| Topoisomerase I inhibitors for the treatment of brain tumors | Q37159504 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 1375-1385 | |
| P577 | publication date | 2019-07-30 | |
| P1433 | published in | Translational Oncology | Q26839583 |
| P1476 | title | DIVERSet JAG Compounds Inhibit Topoisomerase II and Are Effective Against Adult and Pediatric High-Grade Gliomas | |
| P478 | volume | 12 |
Search more.